ROLE OF INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) AND INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 (IGFBP-3) IN THE DIAGNOSIS OF PANCREATIC ADENOCARCINOMA AND MONITORING TREATMENT RESPONSE

Basit Öğe Kaydı
dc.authoridAfsar, Cigdem Usul/0000-0002-3764-7639
dc.authoridSari, Murat/0000-0003-0596-1559
dc.authoriducuncu, Muhammed zubeyr/0000-0003-4638-1059
dc.contributor.authorBademler, Suleyman
dc.contributor.authorUcuncu, Whammed Zubeyr
dc.contributor.authorSari, Murat
dc.contributor.authorYasasever, Ceren Tilgen
dc.contributor.authorAfsar, Cigdem Usul
dc.contributor.authorTastekin, Didem
dc.date.accessioned2024-09-11T19:52:43Z
dc.date.available2024-09-11T19:52:43Z
dc.date.issued2019
dc.departmentİstanbul Gelişim Üniversitesien_US
dc.description.abstractPurpose: Pancreatic cancer occurs rarely in humans, and it is one of the most fatal five cancer types with very poor prognosis. Early diagnosis of pancreatic cancer is difficult due to late presentation of symptoms. The purpose of our study was to evaluate the utility of IGFBP-3 and IGF-1 in early diagnosis of pancreatic cancer and in monitoring treatment response and contribute to the studies conducted in this regard. Methods: The study included 108 subjects, 54 of who were diagnosed with and followed-up for pancreatic cancer and 54 were healthy subjects. The results were compared between the two groups. The study was approved by the Istanbul Faculty of Medicine Ethics Committee. Results: The mean age of the patients included in the study was 54.42 years. IGF-1 levels and IGFBP-3 levels were significantly lower in pancreatic cancer patients than in the control group (respectively p = 0.002, 0.004). There was no difference between IGF-1 and IGFBP-3 levels in patients with distant metastasis (p > 0.05). IGF- 1 levels were significantly higher in patients who responded to chemotherapy than in those who did not respond to chemotherapy (p = 0.03). Conclusions: In our study, we observed that IGF-1 and IGHIP-3 levels can be used for the diagnosis of patients with pancreatic cancer and evaluation of treatment response and prognosis, and there is no significant difference in serum levels according to age, presence of distant metastasis, and gender.en_US
dc.identifier.doi10.19193/0393-6384_2019_1_12
dc.identifier.endpage75en_US
dc.identifier.issn0393-6384
dc.identifier.issn2283-9720
dc.identifier.issue1en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage71en_US
dc.identifier.urihttps://doi.org/10.19193/0393-6384_2019_1_12
dc.identifier.urihttps://hdl.handle.net/11363/8016
dc.identifier.volume35en_US
dc.identifier.wosWOS:000456815700012en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherCarbone Editoreen_US
dc.relation.ispartofActa Medica Mediterraneaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240903_Gen_US
dc.subjectIGF-1 and IGFBP-3 levelsen_US
dc.subjectpancreatic canceren_US
dc.subjectserumen_US
dc.titleROLE OF INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) AND INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 (IGFBP-3) IN THE DIAGNOSIS OF PANCREATIC ADENOCARCINOMA AND MONITORING TREATMENT RESPONSEen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu